Early Detection Research Network


This biomarker is also known as:
  • THBS-1,
  • thrombospondin-1p180,
  • TSP,
  • TSP-1,
  • THBS1,
  • Thrombospondin-1,
  • THBS,


TSP is an adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. TSP can bind to fibrinogen, fibronectin, laminin, type V collagen and integrins alpha-V/beta-1. It has been shown to play roles in platelet aggregation, angiogenesis, and tumorigenesis.


There are no datasets associated with this biomarker.

QA State: Accepted
Type: Protein

The following organs have data associated with this biomarker…


Phase: Two
QA State: Accepted


Blood protein markers that provide more accurate or earlier diagnosis of prostate cancer should have a positive impact on prostate cancer treatment and management. Experimental evidence shows that thrombospondin-1 levels are elevated in patients with benign prostatic disease and repressed in patients with prostate cancer. Thrombospondin-1 levels do not correlate with prostate-specific antigen (PSA) levels and differentiate benign from malignant disease with 79% sensitivity and 81% specificity. The measurement of thrombospondin-1 could be used to assist the decision to obtain a biopsy in men with suspected prostate cancer, which could lead to a reduction in the number of unnecessary prostatic biopsies.

Performance Comment

TSP did not, for the populations tested in these experiments, show strong pre-diagnostic performance. This biomarker has not moved on to Phase 3 study.

Supporting Study Data

The following studies/protocols provide evidence supporting THBS1 indications for the Prostate…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

Organ-Specific Resources

No organ-specific resources defined.

Version 5.0.2